Risk of Recurrence in Patients With HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease Characteristics

医学 肿瘤科 乳腺癌 内科学 疾病 阶段(地层学) 癌症 风险因素 体质指数 古生物学 生物
作者
Joyce O’Shaughnessy,William J. Gradishar,Ruth O’Regan,Vijayakrishna K. Gadi
出处
期刊:Clinical Breast Cancer [Elsevier BV]
卷期号:23 (4): 350-362 被引量:24
标识
DOI:10.1016/j.clbc.2023.03.007
摘要

Human epidermal growth factor receptor 2 (HER2) overexpression occurs in 15% to 20% of patients with early-stage breast cancers (EBCs). Without HER2-targeted therapy, 30% to 50% of patients relapse within 10 years, many developing incurable metastatic disease. This literature review was designed to identify and validate patient- and disease-related factors associated with recurrence in patients with HER2+ EBC. Peer-reviewed primary research articles and congress abstracts were identified by searching MEDLINE. Articles published in English from 2019 to 2022 were included to identify contemporary treatment options. Results were analyzed for the relationship between risk factors and surrogates of HER2+ EBC recurrence to determine how identified risk factors affected HER2+ EBC recurrence. Sixty-one articles and 65 abstracts that assessed age at diagnosis, body mass index (BMI), tumor size at diagnosis, hormone receptor (HR) status, pathologic complete response (pCR) status, and biomarkers were analyzed. We confirmed the results of previously published reviews reporting residual cancer burden >0, non-pCR, and fewer tumor-infiltrating lymphocytes (TILs) as risk factors of recurrence. HR status remained an important risk factor for recurrence, with HER2+/HR+ disease more likely to recur. Two or more positive lymph nodes, higher BMI, larger primary tumor size, and low Ki67 were more commonly associated with HER2+ EBC recurrence. The identification of patient and disease factors frequently associated with HER2+ EBC recurrence in the literature provides insight into potential recurrence risk factors. Further investigation into the risk factors identified in this review could lead to improved treatments for patients at high risk for HER2+ EBC recurrence.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
cyx-buct完成签到,获得积分10
1秒前
yangrui完成签到,获得积分10
1秒前
2秒前
LostCityInWY完成签到,获得积分10
2秒前
水沐菁华完成签到,获得积分10
3秒前
背后的念波完成签到,获得积分10
3秒前
茶多酚发布了新的文献求助10
3秒前
茶多酚发布了新的文献求助10
3秒前
茶多酚发布了新的文献求助10
3秒前
茶多酚发布了新的文献求助10
3秒前
3秒前
情怀的应助被Menand采纳,获得10
4秒前
上官若男的应助被fortuna采纳,获得10
4秒前
5秒前
知性的派大星完成签到,获得积分10
5秒前
6秒前
Lucas的应助被云下采纳,获得10
6秒前
英姑的应助被翟刚采纳,获得10
6秒前
7秒前
7秒前
Owen的应助被涂治鸿采纳,获得10
8秒前
共享精神的应助被魔术师采纳,获得10
8秒前
强健的篮球完成签到,获得积分10
9秒前
9秒前
重要的碧空完成签到,获得积分10
9秒前
9秒前
9秒前
10秒前
11秒前
小二郎的应助被知性的派大星采纳,获得10
11秒前
zdesfsfa发布了新的文献求助10
12秒前
zuizui完成签到,获得积分20
12秒前
12秒前
YAO完成签到 ,获得积分10
12秒前
12秒前
微笑宛儿完成签到,获得积分10
12秒前
13秒前
Miss朱完成签到,获得积分10
13秒前
所所的应助被丫丫采纳,获得10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160632
求助须知:如何正确求助?哪些是违规求助? 9555512
关于积分的说明 21728801
捐赠科研通 7750444
什么是DOI,文献DOI怎么找? 3427429
关于科研通互助平台的介绍 2552456
邀请新用户注册赠送积分活动 2471817